Aphasia. Role of pharmacotherapy in treatment

CNS Drugs

Volumn 7, Issue 3, 1997, Pages 203-213

  Wallesch, Claus W ^a   Müller, Ulrich ^b   Herrmann, Manfred ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CENTRAL STIMULANT AGENT; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; IDAZOXAN; METHYLPHENIDATE; NOOTROPIC AGENT; NORTRIPTYLINE; PHYSOSTIGMINE; PIRACETAM; TRAZODONE;

APHASIA; HUMAN; LINGUISTICS; PRIORITY JOURNAL; REVIEW; SPEECH THERAPY;

EID: 0030999114     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707030-00004     Document Type: Review

References (68)

1. Small SL. Pharmacotherapy of aphasia. Stroke 1994; 25: 1282-9
2. Wallesch CW, Kertesz A. Clinical symptoms and syndromes of aphasia. In: Blanken G, Dittmann J, Grimm H, et al., editors. Linguistic disorders and pathologies. Berlin: De Gruyter, 1993: 98-118
3. Brust J, Shafer S, Richter R, et al. Aphasia in acute stroke. Stroke 1976; 7: 167-74
4. Pedersen PM, Jorgensen HS, Nakayama H, et al. Aphasia in acute stroke: incidence, determinants and recovery. Ann Neurol 1995; 38: 659-66
5. Willmes K, Poeck K. Ergebnisse einer multizentrischen Untersuchung über die Spontanprognose von Aphasien vaskulärer Ätiologie. Nervenarzt 1984; 55: 62-71
6. von Stockert TR. Aphasia sine aphasia. Brain Lang 1975; 1: 277-82
7. Rubens AB. Transcortical motor aphasia. In: Whitaker H, Whitaker HA, editors. Studies in neurolinguistics, vol. I. New York: Academic Press, 1976: 293-303
8. Buckingham HW, Whitaker H, Whitaker HA. On linguistic perseveration. In: Whitaker H, Whitaker HA, editors. Studies in neurolinguistics, vol. 4. New York: Academic Press, 1979: 329-52
9. Brain WR. Speech disorders. London: Butterworth, 1965
10. Wallesch CW. Repetitive verbal behaviour: neurological and functional considerations. Aphasiology 1990; 4: 133-54
11. Lyon M, Robbins T. The action of central nervous stimulant drugs: a general theory concerning amphetamine effects. In: Essmann W, Valzelli L, editors. Current developments in psychopharmacology, vol. 2. New York: Spectrum, 1975: 79-163
12. Herrmann M, Bartels C, Wallesch CW. Depression in acute and chronic aphasia: symptoms, pathoanatomical-clinical correlations and functional implications. J Neurol Neurosurg Psychiatry 1993; 56: 672-8
13. Poeck K, Huber W, Willmes K. Outcome of intensive language treatment in aphasia. J Speech Hear Disord 1989; 54: 471-9
14. Luria AR, Naydin VL, Tsvetkova LS, et al. Restoration of higher cortical function following local brain damage. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology, vol. 3. Amsterdam: North Holland, 1969: 368-433
15. Jacobs DH, Shuren J, Gold M, et al. Physostigmine pharmacotherapy for aphasia. Neurocase 1996; 2: 83-92
16. Sandson J, Albert ML. Perseveration in behavioral neurology. Neurology 1987; 37: 1736-41
17. Feeney DM, Weisend MP, Kline AE. Noradrenergic pharmacotherapy, intracerebral infusion and adrenal transplantation promote functional recovery after cortical damage. J Neural Transplant Plast 1993; 4: 199-213
18. Boyeson MG, Feeney DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharmacol Biochem Behav 1990; 35: 497-501
19. Feeney DM. Pharmacological modulation of recovery after brain injury: a reconsideration of diaschisis. J Neurol Rehabil 1991; 5: 113-28
20. Albert ML, Bachman DL, Morgan A, et al. Pharmacotherapy for aphasia. Neurology 1988; 38: 877-9
21. Gupta SR, Mlcoch AG. Bromocriptine treatment of nonfluent aphasia. Arch Phys Med Rehabil 1992; 73: 373-6
22. Sabe L, Leiguarda R, Starkstein SE. An open-label trial of bromocriptine in nonfluent aphasia. Neurology 1992; 42: 1637-8
23. Sabe L, Salvarezza F, Cuerva AG, et al. A randomized, double blind, placebo control led study of bromocriptine in nonfluent aphasia. Neurology 1995; 45: 2272-4
24. Gupta SR, Mlcoch AG, Scolaro C, et al. Bromocriptine treatment of nonfluent aphasia. Neurology 1995; 45: 2170-3
25. Leiguarda L, Merello M, Sabe L, et al. Bromocriptine induced dystonia in patients with aphasia and hemiparesis. Neurology 1993; 43: 2319-22
26. Alexander G, DeLong M, Strick P. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81
27. Wallesch CW, Papagno C. Subcortical aphasia. In: Rose FC, Whurr R, Wyke MA, editors. Aphasia. London: Whurr, 1989: 256-87
28. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science 1982; 217: 855-7
29. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walking after sensorimotor cortex lesion in the rat. Brain Res 1990; 508: 305-9
30. Sutton RL, Feeney DM. α-Noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation. Restor Neurol Neurosci 1992; 4: 1-11
31. Crisostomo EA, Duncan PW, Propst M, et al. Evidence that amphetamine with physical therapy promotes recovery of function in stroke patients. Ann Neurol 1988; 23: 94-7
32. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence. Stroke 1995; 26: 2254-9
33. Walker-Batson D, Unwin H, Curtis S, et al. Use of amphetamine in the treatment of aphasia. Restor Neurol Neurosci 1992; 4: 47-50
34. Porch B, Callaghan S. Making predictions about recovery: is there HOAP.In: Brookshire RH, editor. Clinical aphasiology: conference proceedings. Minneapolis: BRK, 1981: 187-200
35. Müller U, Ziegler W, von Cramon DY. Amphetamine in apraxia of speech [abstract]. Neuropsychopharmacology 1994; 10 Suppl. 3: 226
36. Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl) 1993; 111: 1-16
37. Halliday R, Naylor H, Brandeis D, et al. The effect of D-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology 1994; 31: 331-7
38. Stitzer ML, Griffiths RR, Liebson I. Effects of d-amphetamine on speaking in isolated humans. Pharmacol Biochem Behav 1978; 9: 57-63
39. Higgins ST, Stitzer ML. Monologue speech: effects of d-amphetamine, secobarbital and diazepam. Pharmacol Biochem Behav 1989; 34: 609-18
40. Coull JT, Sahakian BJ, Hodges JR. The α2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology 1996; 123: 239-49
41. Willmes K, Huber W, Poeck K, et al. Die Wirkung von Piracetam bei der logopädischen Intensivtherapie von chronisch aphasischen Patienten. In: Helmchen H, editor. Wirkungen und Wirksamkeit von Nootropika. Berlin: Springer, 1988
42. Enderby P, Broeckx J, Hospers W, et al. Effect of piracetam on recovery and rehabilitation after stroke: a double blind, placebo-controlled study. Clin Neuropharmacol 1994; 17: 320-31
43. Lipsey JR, Robinson RG. Depression: a frequently untreated complication of stroke. Med Aspects Hum Sex 1987; 21: 57-69
44. Damecour CL, Caplan D. The relationship of depression to symptomatology and lesion site in aphasie patients. Cortex 1991; 27: 385-401
45. Robinson RG, Szetela B. Mood change following left hemispheric brain injury. Ann Neurol 1981; 9: 447-53
46. Starkstein SE, Robinson RG. Aphasia and depression. Aphasiology 1988; 2: 1-20
47. Herrmann M, Bartels C, Schumacher M, et al. Poststroke depression: is there a pathoanatomical correlate for depression following the postacute stage of stroke? Stroke 1995; 26: 850-6
48. Mayberg HS, Robinson RG, Wong DF, et al. PET imaging of cortical S2-serotonin receptors after stroke - laterilized changes and relationship to depression. Am J Psychiatry 1988; 145: 937-43
49. Charatan FB, Fisk A. Mental and emotional results of stroke. N Y State J Med 1978; 78: 1403-5
50. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double blind treatment trial. Lancet 1984; 1: 297-300
51. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol 1986; 43: 763-5
52. Balunov OA, Sadov OG, Alemasova AY. Therapy of depressions in post-stroke patients. Alaska Med 1990; 32: 27-9
53. Finklestein SP, Weintraub RJ, Karmouz N, et al. Antidepressant drug treatment for poststroke depression: retrospective study. Arch Phys Med Rehabil 1992; 68: 772-6
54. Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150: 286-93
55. Johnson ML, Roberts MD, Ross AR, et al. Methylphenidate in stroke patients with depression. Am J Phys Med Rehabil 1992; 71: 239-41
56. Lingam VR, Lazarus LW, Groves L, et al. Methylphenidate in treating poststroke depression. J Clin Psychiatry 1988; 49: 151-3
57. Lazarus LW, Winemiller DR, Lingam VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992; 53: 447-9
58. Masand P, Murray GB, Pickett P. Psychostimulants in poststroke depression. J Neuropsychiatry Clin Neurosci 1991; 3: 23-7
59. Murray GB, Shea V, Conn DK. Electroconvulsive therapy for poststroke depression. J Clin Psychiatry 1986; 47: 258-60
60. Currier MB, Murray GB, Welch CC. Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992; 4: 140-4
61. Andersen G, Veestergard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099-104
62. Andersen G, Vestergaard K, Riis J. Citalopram for post-stroke pathological crying. Lancet 1993; 342: 837-9
63. Andersen G. Post-stroke depression and pathological crying: clinical aspects and new pharmacological approaches. Aphasiology. In press
64. Müller U, von Cramon DY. The therapeutic potential of bromo-criptine in neuropsychological rehabilitation of patients with acquired brain damage. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1103-20
65. Robbins TW, Mittleman G, O'Brien J, et al. The neuropsychological significance of stereotypy induced by stimu-lant drugs. In: Cooper SJ, Dourish CT. editors. Neurobiology of stereotyped behaviour. Oxford: Clarendon, 1990: 25-63
66. Feeney DM, Westerberg VS. Norepinephrine and brain damage: alpha-noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol 1990; 44: 233-52
67. Solomen S, Hotchkiss E, Sarvay SM, et al. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry 1983; 40: 1109-12
68. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271-7